Multiple Sclerosis – Drug Pipeline Analysis and Market Forecasts to 2015
12/22/2009

Multiple Sclerosis Therapeutics Market is Forecast to Show Significant Growth until 2015

Online PR News – 22-December-2009 – – GlobalData estimated the global MS market to be valued at $8.7 billion in 2008. This market is forecast to grow at 4% annually for the next seven years to reach $11.4 billion by 2015. This growth is primarily attributed to strong current treatment options as well as strong pipeline candidates. The growth will be further supported by high incidence and prevalence rates of disease, and the high prescription rate of current marketed products. However, the barriers for the MS market like low treatment seeking rate, low diagnosis rate and availability of alternative options will cause restriction in market size.

For further details, please click or add the following link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Multiple-Sclerosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData found that more than 130 products are in different developmental stages. Mylinax in regulatory filing, Teriflunomide, BG-12, Fingolimod (FTY720), and Laquinimod currently in Phase III, are the key products in pipeline. These late stage pipeline products with features such as induction of remyelination, reduction in lesion and relapses, more patient compliant doses forms with reduced side effects remain the most keenly watched products in pipeline. If successfully launched these products are expected to meet patients’ expectation. Furthermore, it may lead to an intensely competitive market landscape.

For further details, please click or add the following link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Multiple-Sclerosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData found that Biogen Idec, Teva Pharmaceutical, Merck Serono and Bayer Schering Pharma remain the leading competitors in the global MS market. Together, these companies accounted for approximately 99% of the global market share in 2008. Biogen Idec with Avonex and Tysabri remained the market leader with a share of approximately 30%. However, companies like Biogen Idec, Merck Serono, Sanofi Aventis, AstraZeneca and Glenmark with some of the most technologically advanced products in their pipeline portfolio, are expected to attract the most of investors’ attention. The global MS market has seen intense competition which is expected to further intensify in the coming years.

GlobalData, the industry analysis specialist, has released a new report, “Multiple Sclerosis – Drug Pipeline Analysis and Market Forecasts to 2015”. The report is an essential source of information and analysis on the global Multiple Sclerosis (MS) market. The report identifies the key trends shaping and driving the global MS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global MS sector.

For further details, please click or add the following link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Multiple-Sclerosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

Or visit our report store: http://www.globaldata.com/reportstore